| Anywhere Foot And Ankle Care | |
|
3820 Del Amo Blvd Ste 215, Torrance, CA 90503-2148 | |
| (310) 750-4511 | |
| (213) 270-9373 |
| Full Name | Anywhere Foot And Ankle Care |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 3820 Del Amo Blvd Ste 215, Torrance, California |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306339759 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | (* (Not Available)) | Primary |
| Provider Name | Mai Kim Dan Truong |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1992724512 PECOS PAC ID: 5193714186 Enrollment ID: I20040506000709 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Jonathan Tiongson |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1487607685 PECOS PAC ID: 8921071499 Enrollment ID: I20090317000470 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Phong H Le |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1316191166 PECOS PAC ID: 3971767237 Enrollment ID: I20120618000296 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Lisa Nhan |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1811288418 PECOS PAC ID: 1850513706 Enrollment ID: I20141110002344 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Lauren Priya Singh |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1376887323 PECOS PAC ID: 5597079145 Enrollment ID: I20150727002919 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Andrew L Camarena |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1407106321 PECOS PAC ID: 7810206166 Enrollment ID: I20151027002741 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Robert Leaming |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1215374699 PECOS PAC ID: 1759677503 Enrollment ID: I20160906000647 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Jeffrey M Demian |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1922477280 PECOS PAC ID: 8820356900 Enrollment ID: I20171219000457 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Danielle V Mcneil |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1467772715 PECOS PAC ID: 4284861121 Enrollment ID: I20180103001834 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Michael Shen |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1366806291 PECOS PAC ID: 7214260801 Enrollment ID: I20190613002105 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Neil B Patel |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1093262099 PECOS PAC ID: 1850629916 Enrollment ID: I20190827003660 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Michael H. Kim-orden |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1326457839 PECOS PAC ID: 5698004117 Enrollment ID: I20190909003733 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Nshan D Dekeyan |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1932623659 PECOS PAC ID: 5193147213 Enrollment ID: I20200618002116 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Tyson Marquis Schmidthuber |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1053830463 PECOS PAC ID: 9234558370 Enrollment ID: I20200924000459 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Adrienne Y. Doi |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1679008049 PECOS PAC ID: 2365862844 Enrollment ID: I20201022000743 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Billy Yu |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1578084653 PECOS PAC ID: 4486064615 Enrollment ID: I20201029001083 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Rotem Benad Korsnack |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1497076962 PECOS PAC ID: 7810310711 Enrollment ID: I20201104000959 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Zachary James Gustin |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1134779820 PECOS PAC ID: 9739580291 Enrollment ID: I20210622002800 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Dustin Rilling |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1437701091 PECOS PAC ID: 5395148142 Enrollment ID: I20210730001649 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Warda Saarah Shamshad |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1154842755 PECOS PAC ID: 6406247162 Enrollment ID: I20220106002676 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Dana Lin |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1811481914 PECOS PAC ID: 8426458878 Enrollment ID: I20220411001652 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Nisha Ketan Desai |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1598326464 PECOS PAC ID: 6204213135 Enrollment ID: I20220516001862 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Helen Shnol |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1295258366 PECOS PAC ID: 4880025782 Enrollment ID: I20220811000240 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Karuna Xaymountry |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1184283137 PECOS PAC ID: 8527442656 Enrollment ID: I20220908001592 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Suchir Sheth |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1982050209 PECOS PAC ID: 9133452840 Enrollment ID: I20230309000663 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Mina Sarbaz |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1609438647 PECOS PAC ID: 7517332331 Enrollment ID: I20230410001923 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Elizabeth Hana Oh |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1073142394 PECOS PAC ID: 8123459922 Enrollment ID: I20230522001826 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Provider Name | Opal Patel |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1114547056 PECOS PAC ID: 2264893635 Enrollment ID: I20230801003478 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anywhere Foot And Ankle Care 22633 Anza Ave, Torrance, CA 90505-3418 Ph: (310) 978-7579 | Anywhere Foot And Ankle Care 3820 Del Amo Blvd Ste 215, Torrance, CA 90503-2148 Ph: (310) 750-4511 |
News Archive
A majority of hospitalized patients favor eliminating processed meats-including bacon, deli meat, and sausage-from hospital menus to reduce cancer risk, according to a new survey published in the Journal of Hospital Management and Health Policy.
Cell-derived exosomes are effective in treating disease when mixed with the dominant protein in breast milk and given orally, a new Smidt Heart Institute study of laboratory mice shows.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 9 days ago
Marc Alan Benard, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3812 Sepulveda Blvd, Suite 530, Torrance, CA 90505 Phone: 310-530-8001 Fax: 310-375-1386 | |
E.t. Foot & Ankle Podiatrist Medicare: Medicare Enrolled Practice Location: 23365 Hawthorne Blvd Ste 101, Torrance, CA 90505 Phone: 714-851-7775 | |
Arnold Serkin, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 3400 Lomita Blvd Ste 403, Torrance, CA 90505 Phone: 310-326-8551 | |
Dr. Carl Wagreich, D.P.M. Podiatrist Medicare: May Accept Medicare Assignments Practice Location: 23451 Madison St, Ste 230, Torrance, CA 90505 Phone: 310-373-0521 Fax: 310-791-1691 | |
Dr. Nina Argade, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 3655 Lomita Blvd, Ste 120, Torrance, CA 90505 Phone: 562-933-2000 | |
Dr. Randall William Leyking, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 21250 Hawthorne Blvd, Suite 160, Torrance, CA 90503 Phone: 310-540-1213 Fax: 310-540-7405 | |
Focused Foot Care Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 17521 Crenshaw Blvd, Torrance, CA 90504 Phone: 310-963-6229 |